Home › Prostate Cancer › NCT06355336
Real World Prostate Cancer Registry
Patient Reported Data on Prostate Cancer Diagnosis, Management, and Outcome: Real World Prostate Cancer Registry
Who can join
Ages 18 and older · Men
Full eligibility criteria
Inclusion Criteria: All patients with pathologically confirmed primary prostate cancer Diagnosis since January 1st, 2023 Acceptance to sign the consent form 18 years old or older Resident of Ohio, Kentucky or Indiana Exclusion Criteria: Having diagnosis of other cancer except squamous cell cancer of the skin Refusal to sign a consent form.
About the study
Prostate cancer is the most common cancer diagnosed in men in the USA with 268,490 cases diagnosed in 2022 constituting 27% of male cancers and 34,500 deaths (11%) occurred in same year.1 Prostate cancer is a very heterogeneous disease that has different presentations, molecular and pathological features, stages, and disease biology. The treatment options are dependent on the disease stage, its features, and the patient's condition and preferences. The disease outcome also varies significantly due to the previous heterogeneity of the features in addition to other social determinants of health.
Therefore, it is critical to obtain real-world data that reflects the actual patterns of prostate cancer presentation, work up, management, and outcome. Real World Prostate Cancer Registry (RWPCR) aims at compiling real world data from patients presented with prostate cancer in the tristate area. The data collection will be prospective and longitudinal including patients' demographics and disease characteristics, work up, management, and outcome.
Sponsor: Cincinnati Cancer Advisors · Participants: 1,000 · Started: Mar 18, 2024
Contact the study team
- Abdul Jazieh, MD, MPH · Phone: 5137312273
- Amy Barber · Phone: 5137312273
Official record on ClinicalTrials.gov — NCT06355336
Locations in the U.S.
| Ohio | Cincinnati Cancer Advisors, Cincinnati |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.